Roflumilast, a Type 4 phosphodiesterase inhibitor, shows promising adjunctive, host-directed therapeutic activity in a mouse model of tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7888-7890

  Maiga, Mariama C ^a,b,d   Ahidjo, Bintou Ahmadou ^a,b   Maiga, Mamoudou ^a,c   Bishai, William R ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c Sociétés   (Mali)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; ISONIAZID; ROFLUMILAST; TUMOR NECROSIS FACTOR ALPHA; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR;

ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CLEARANCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FOOD AND DRUG ADMINISTRATION; MEDIAN SURVIVAL TIME; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DISEASE MODEL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; LUNG; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; SURVIVAL ANALYSIS; TUBERCULOSIS, PULMONARY;

AMINOPYRIDINES; ANIMALS; ANTITUBERCULAR AGENTS; BENZAMIDES; CYCLOPROPANES; DISEASE MODELS, ANIMAL; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-1BETA; ISONIAZID; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PHOSPHODIESTERASE 4 INHIBITORS; SURVIVAL ANALYSIS; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84954570108     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02145-15     Document Type: Article

References (16)

1. Wallis RS, Hafner R. 2015. Advancing host-directed therapy for tuberculosis. Nat Rev Immunol 15:255-263. http://dx.doi.org/10.1038 /nri3813.
2. Maiga M, Agarwal N, Ammerman NC, Gupta R, Guo H, Maiga MC, Lun S, Bishai WR. 2012. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS One 7:e30749. http://dx.doi.org/10.1371/journal.pone.0030749.
3. Zhang HT. 2009. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des 15:1688-1698. http://dx.doi.org/10.2174/138161209788168092.
4. Ordonez AA, Maiga M, Gupta S, Weinstein EA, Bishai WR, Jain SK. 2014. Novel adjunctive therapies for the treatment of tuberculosis. Curr Mol Med 14:385-395. http://dx.doi.org/10.2174/1566524013666131118112431.
5. Koo MS, Manca C, Yang G, O'Brien P, Sung N, Tsenova L, Subbian S, Fallows D, Muller G, Ehrt S, Kaplan G. 2011. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS One 6:e17091. http://dx.doi.org/10.1371/journal.pone.0017091.
6. Maiga M, Ammerman NC, Maiga MC, Tounkara A, Siddiqui S, Polis M, Murphy R, Bishai WR. 2013. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J Infect Dis 208:512-519. http://dx.doi.org/10.1093/infdis/jit187.
7. Rao YJ, Xi L. 2009. Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Acta Pharmacol Sin 30:1-24. http://dx.doi.org/10.1038/aps.2008.1.
8. Giembycz MA, Field SK. 2010. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Dev Ther 4:147-158. http://dx.doi.org/10.2147/DDDT.S7667.
9. Rieder F, Siegmund B, Bundschuh DS, Lehr HA, Endres S, Eigler A. 2013. The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice. PLoS One 8:e56867. http://dx.doi.org/10.1371/journal.pone.0056867.
10. Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J. 2009. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 53:4178-4184. http://dx.doi.org/10.1128/AAC.00830-09.
11. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, Derrick SC, Shi R, Kumar NP, Wei W, Yuan X, Zhang G, Cai Y, Babu S, Catalfamo M, Salazar AM, Via LE, Barry CE, III, Sher A. 2014. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511:99-103. http://dx.doi.org/10.1038 /nature13489.
12. Ahmad Z, Klinkenberg LG, Pinn ML, Fraig MM, Peloquin CA, Bishai WR, Nuermberger EL, Grosset JH, Karakousis PC. 2009. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drugresistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis 200: 1136-1143. http://dx.doi.org/10.1086/605605.
13. Fauvart M, De Groote VN, Michiels J. 2011. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J Med Microbiol 60:699-709. http://dx.doi.org/10.1099/jmm.0.030932-0.
14. Subbian S, Tsenova L, O'Brien P, Yang G, Koo MS, Peixoto B, Fallows D, Dartois V, Muller G, Kaplan G. 2011. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog 7:e1002262. http: //dx.doi.org/10.1371/journal.ppat.1002262.
15. Agarwal N, Lamichhane G, Gupta R, Nolan S, Bishai WR. 2009. Cyclic AMP intoxication of macrophages by aMycobacterium tuberculosis adenylate cyclase. Nature 460:98-102. http://dx.doi.org/10.1038/nature08123.
16. Shanks N, Greek R, Greek J. 2009. Are animal models predictive for humans? Philos Ethics Humanit Med 4:2. http://dx.doi.org/10.1186/1747-5341-4-2.